ATX-304

1. ATX-304 increases resting metabolic rate in humans (up to 33%).

   “Resting metabolic rate assessed by indirect calorimetry increased up to 33% compared to baseline”

   Human trialprediabetic obese subjects400 mg once daily8 to 16 weeks

   Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

1. ATX-304 decreases visceral fat in humans.

   “reduced liver and visceral fat assessed by MRI in a time-dependent manner”

   Human trialprediabetic obese subjectsvisceral adipose tissue400 mg once daily8 to 16 weeks

   Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

1. ATX-304 decreases liver fat in humans.

   “reduced liver and visceral fat assessed by MRI in a time-dependent manner”

   Human trialprediabetic obese subjectsliver400 mg once daily8 to 16 weeks

   Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

1. ATX-304 increases adiponectin in humans.

   “Compared to baseline, ATX significantly increased total adiponectin in plasma”

   Human trialprediabetic obese subjectsplasma400 mg once daily8 to 16 weeks

   Phase 1b Study of AMPK/Mitochondrial Activator ATX-304 in Prediabetic Obese Participants

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Adiponectin